Canada Markets close in 29 mins

Prenetics Global Limited (PRE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.4780-0.0220 (-1.47%)
As of 03:22PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close1.5000
Open1.5000
Bid1.4500 x 1100
Ask1.4800 x 1100
Day's Range1.4589 - 1.5200
52 Week Range1.2400 - 8.7500
Volume120,049
Avg. Volume889,486
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.55
  • GlobeNewswire

    Prenetics Announces Dr. Bayju Thakar as Chief Executive Officer of Prenetics EMEA

    LONDON and HONG KONG, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) a leader in genomic and diagnostic testing, today announced an executive leadership change to ensure the company realizes the full potential of its broad genetics and digital testing platform and as a commitment to the EMEA market. To be effective immediately, Dr. Bayju Thakar is appointed as CEO and shall join the board of directors for Prenetics EMEA Limited (“Prenetics EMEA”), a wholly owned subsidi

  • ACCESSWIRE

    Sidoti's January Micro-Cap Conference

    Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursday, January 18-19, 2023.

  • GlobeNewswire

    Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco, the First Asia-Based Company to Receive Clearance for a Comprehensive Genomic Profiling Test for All Solid Tumors

    Prenetics has completed the majority stake acquisition of ACT Genomics to spearhead its entry into to the US$80+ billion global precision oncology marketFDA market authorization advances personalized cancer care in AsiaClearance sets the stage for continued R&D investment into early detection / liquid biopsy LONDON and HONG KONG, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) a leader in genomic and diagnostic testing, today announced that ACT Genomics, a company which